| pubmed-article:9441773 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9441773 | lifeskim:mentions | umls-concept:C0677886 | lld:lifeskim |
| pubmed-article:9441773 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:9441773 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:9441773 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:9441773 | lifeskim:mentions | umls-concept:C0085101 | lld:lifeskim |
| pubmed-article:9441773 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:9441773 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9441773 | pubmed:dateCreated | 1998-2-4 | lld:pubmed |
| pubmed-article:9441773 | pubmed:abstractText | Epithelial ovarian cancer (EOC) is known to produce carcinoembryonic antigen (CEA), and the plasma CEA level is frequently elevated in patients with advanced stage and bulk of tumor. This study reports the results of a phase I therapy trial with intravenously administered 131I-MN-14 anti-CEA monoclonal antibody (MAb) in patients with EOC. | lld:pubmed |
| pubmed-article:9441773 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9441773 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9441773 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9441773 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9441773 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9441773 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9441773 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9441773 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9441773 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9441773 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9441773 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:9441773 | pubmed:issn | 0090-8258 | lld:pubmed |
| pubmed-article:9441773 | pubmed:author | pubmed-author:GoldenbergD... | lld:pubmed |
| pubmed-article:9441773 | pubmed:author | pubmed-author:DunnRR | lld:pubmed |
| pubmed-article:9441773 | pubmed:author | pubmed-author:HerskovicTT | lld:pubmed |
| pubmed-article:9441773 | pubmed:author | pubmed-author:SharkeyR MRM | lld:pubmed |
| pubmed-article:9441773 | pubmed:author | pubmed-author:RubinA DAD | lld:pubmed |
| pubmed-article:9441773 | pubmed:author | pubmed-author:JuweidMM | lld:pubmed |
| pubmed-article:9441773 | pubmed:author | pubmed-author:SwayneL CLC | lld:pubmed |
| pubmed-article:9441773 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9441773 | pubmed:volume | 67 | lld:pubmed |
| pubmed-article:9441773 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9441773 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9441773 | pubmed:pagination | 259-71 | lld:pubmed |
| pubmed-article:9441773 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:meshHeading | pubmed-meshheading:9441773-... | lld:pubmed |
| pubmed-article:9441773 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9441773 | pubmed:articleTitle | Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. | lld:pubmed |
| pubmed-article:9441773 | pubmed:affiliation | Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA. | lld:pubmed |
| pubmed-article:9441773 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9441773 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9441773 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9441773 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9441773 | lld:pubmed |
